NRx Pharmaceuticals (Nasdaq:NRXP) announces elimination of all balance sheet debt following equity conversion

Core Insights - NRx Pharmaceuticals has repaid its remaining $5.4 million debt to Anson Funds through equity conversion of common stock, eliminating all outstanding debt from its balance sheet [1][5] - The company anticipates a debt-free balance sheet by December 31, 2025, which is expected to facilitate accelerated growth in 2026, including potential drug approvals and clinic expansions [1][5] - NRx is focused on developing therapeutics for central nervous system disorders, specifically targeting suicidal depression and PTSD, with key products NRX-100 and NRX-101 [3] Financial Overview - The total amount originally lent by Anson Funds was $16.2 million, which was used for repaying prior loans and corporate operating expenses [1] - The repayment of the $5.4 million debt marks a significant milestone for the company, positioning it for future growth [1][5] Product Development - NRx is developing NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral D-cycloserine/lurasidone, both aimed at treating suicidal ideation in depression [3] - NRX-100 has received Fast Track Designation, while NRX-101 has been awarded Breakthrough Therapy Designation for treating suicidal bipolar depression [3]